Tinea Corporis Market Research Report Information By drug type (antifungals and others), by diagnosis (physical exam, imaging test, and others), by treatment (antifungal shampoos and others), by end-users (hospital pharmacies and others)- Forecast till 2032

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Tinea Corporis Market, by Drug Type

6.1 Introduction

6.2 Antifungals

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3 Steroids

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.4 Anti-Infective Combinations

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 7. Global Tinea Corporis Market, by Diagnosis

7.1 Introduction

7.2 Physical Exam

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3 Imaging Tests

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.1 Wood Lamp (Black Light) Examination

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.2 Microscopy Using Potassium Hydroxide (KOH)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.3 Fungal Culture

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.4 Skin Biopsy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.5 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 8. Global Tinea Corporis Market, by Treatmant

8.1 Introduction

8.2 Antifungal Shampoos

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.3 Antifungal Creams

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.4 Drugs

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.5 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 9. Global Tinea Corporis Market, by End-Users

9.1 Introduction

9.2 Hospital Pharmacies

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.3 Drug Stores

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.4 Online Pharmacies

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.5 Dermatology hospitals

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.6 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 10. Global Tinea Corporis Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia-Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 South Korea

10.4.6 Rest of Asia-Pacific

10.5 Middle East & Africa

10.5.1 Middle East

10.5.2 Africa

Chapter 11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

Chapter 12. Company Profiles

12.1 Astellas Pharma

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials Overview

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.2 Bayer AG

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Enzon Pharmaceuticals, Inc

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Galderma S.A.

12.4.1 Company Overview

12.4.2 Product Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Gilead

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 Novartis AG

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Pfizer Inc

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financial Overview

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.12 Taro Pharmaceutical Industries Ltd

12.12.1 Overview

12.12.2 Product Overview

12.12.3 Financials

12.12.4 Key Developments

12.12.5 SWOT Analysis

12.7 Teva Pharmaceutical Industries Ltd

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.12 Valeant

12.12.1 Overview

12.12.2 Product Overview

12.12.3 Financials

12.12.4 Key Developments

12.12.5 SWOT Analysis

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Predictions for the Tinea Corporis Market

Chapter 14. Appendix

LIST OF TABLES

Table 1 Global Tinea Corporis Market Synopsis, 2020–2027

Table 2 Global Tinea Corporis Market Estimates and Forecast, 2020–2027 (USD Million)

Table 3 Global Tinea Corporis Market, by Region, 2020–2027 (USD Million)

Table 4 Global Tinea Corporis Market, by Drug Type, 2020–2027 (USD Million)

Table 5 Global Tinea Corporis Market, by Diagnosis, 2020–2027 (USD Million)

Table 6 Global Tinea Corporis Market, by Treatmant, 2020–2027 (USD Million)

Table 7 Global Tinea Corporis Market, by End-Users, 2020–2027 (USD Million0

Table 8 North America: Tinea Corporis Market, by Drug Type, 2020–2027 (USD Million)

Table 9 North America: Tinea Corporis Market, by Diagnosis, 2020–2027 (USD Million)

Table 10 North America: Tinea Corporis Market, by Treatment, 2020–2027 (USD Million)

Table 11 North America: Tinea Corporis Market, by End-Users , 2020–2027 (USD Million)

Table 12 US: Tinea Corporis Market, by Drug Type, 2020–2027 (USD Million)

Table 13 US: Tinea Corporis Market, by Diagnosis, 2020–2027 (USD Million)

Table 14 US: Tinea Corporis Market, by Treatment, 2020–2027 (USD Million)

Table 15 US: Tinea Corporis Market, by End-Usesr, 2020–2027 (USD Million)

Table 16 Canada: Tinea Corporis Market, by Drug Type, 2020–2027 (USD Million)

Table 17 Canada: Tinea Corporis Market, by Diagnosis, 2020–2027 (USD Million)

Table 18 Canada: Tinea Corporis Market, by Treatment, 2020–2027 (USD Million)

Table 19 Canada: Tinea Corporis Market, by End-Users, 2020–2027 (USD Million)

Table 20 South America: Tinea Corporis Market, by Drug Type, 2020–2027 (USD Million)

Table 21 South America: Tinea Corporis Market, by Diagnosis, 2020–2027 (USD Million)

Table 22 South America: Tinea Corporis Market, by Treatment, 2020–2027 (USD Million)

Table 23 South America: Tinea Corporis Market, by End-Usesr, 2020–2027 (USD Million)

Table 24 Europe: Tinea Corporis Market, by Drug Type, 2020–2027 (USD Million)

Table 25 Europe: Tinea Corporis Market, by Diagnosis, 2020–2027 (USD Million)

Table 26 Europe: Tinea Corporis Market, by Treatment, 2020–2027 (USD Million)

Table 27 Europe: Tinea Corporis Market, by End-Usesr, 2020–2027 (USD Million)

Table 28 Western Europe: Tinea Corporis Market, by Drug Type, 2020–2027 (USD Million)

Table 29 Western Europe: Tinea Corporis Market, by Diagnosis, 2020–2027 (USD Million)

Table 30 Western Europe: Tinea Corporis Market, by Treatment, 2020–2027 (USD Million)

Table 31 Western Europe: Tinea Corporis Market, by End-Users, 2020–2027 (USD Million)

Table 32 Eastern Europe: Tinea Corporis Market, by Drug Type, 2020–2027 (USD Million)

Table 33 Eastern Europe: Tinea Corporis Market, by Diagnosis, 2020–2027 (USD Million)

Table 34 Eastern Europe: Tinea Corporis Market, by Treatment, 2020–2027 (USD Million)

Table 35 Eastern Europe: Tinea Corporis Market, by End-Usesr, 2020–2027 (USD Million)

Table 36 Asia-Pacific: Tinea Corporis Market, by Drug Type, 2020–2027 (USD Million)

Table 37 Asia-Pacific: Tinea Corporis Market, by Diagnosis, 2020–2027 (USD Million)

Table 38 Asia-Pacific: Tinea Corporis Market, by Treatment, 2020–2027 (USD Million)

Table 39 Asia-Pacific: Tinea Corporis Market, by End-Usesr, 2020–2027 (USD Million)

Table 40 Middle East & Africa: Tinea Corporis Market, by Drug Type, 20132-2027 (USD Million)

Table 41 Middle East & Africa: Tinea Corporis Market, by Diagnosis, 2020–2027 (USD Million)

Table 42 Middle East & Africa: Tinea Corporis Market, by Treatment, 2020–2027 (USD Million)

Table 43 Middle East & Africa: Tinea Corporis Market, by End-Usesr, 2020–2027 (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Tinea Corporis Market

Figure 3 Segmentation Market Dynamics for Global Tinea Corporis Market

Figure 4 Global Tinea Corporis Market Share, by Drug Type, 2020

Figure 5 Global Tinea Corporis Market Share, by Diagnosis, 2020

Figure 6 Global Tinea Corporis Market Share, by Treatment, 2020

Figure 7 Global Tinea Corporis Market Share, by End-Users, 2020

Figure 8 Global Tinea Corporis Market Share, by Region, 2020

Figure 9 North America: Tinea Corporis Market Share, by Country, 2020

Figure 10 Europe: Tinea Corporis Market Share, by Country, 2020

Figure 11 Asia-Pacific: Tinea Corporis Market Share, by Country, 2020

Figure 12 Middle East & Africa: Tinea Corporis Market Share, by Country, 2020

Figure 13 Global Tinea Corporis Market: Company Share Analysis, 2020 (%)

Figure 14 Astellas Pharma: Key Financials

Figure 15 Astellas Pharma: Segmental Revenue

Figure 16 Astellas Pharma: Geographical Revenue

Figure 17 Bayer AG : Key Financials

Figure 18 Bayer AG : Segmental Revenue

Figure 19 Bayer AG : Geographical Revenue

Figure 20 Enzon Pharmaceuticals, Inc: Key Financials

Figure 21 Enzon Pharmaceuticals, Inc: Segmental Revenue

Figure 22 Enzon Pharmaceuticals, Inc: Geographical Revenue

Figure 23 Galderma S.A. : Key Financials

Figure 24 Galderma S.A. : Segmental Revenue

Figure 25 Galderma S.A. : Geographical Revenue

Figure 26 Gilead : Key Financials

Figure 27 Gilead : Segmental Revenue

Figure 28 Gilead . Geographical Revenue

Figure 29 Novartis AG : Key Financials

Figure 30 Novartis AG : Segmental Revenue

Figure 31 Novartis AG : Geographical Revenue

Figure 32 Pfizer Inc: Key Financials

Figure 33 Pfizer Inc: Segmental Revenue

Figure 34 Pfizer Inc: Geographical Revenue

Figure 35 Taro Pharmaceutical Industries Ltd: Key Financials

Figure 36 Taro Pharmaceutical Industries Ltd: Segmental Revenue

Figure 37 Taro Pharmaceutical Industries Ltd: Geographical Revenue

Figure 38 Teva Pharmaceutical Industries Ltd: Key Financials

Figure 39 Teva Pharmaceutical Industries Ltd: Segmental Revenue

Figure 40 Teva Pharmaceutical Industries Ltd: Geographical Revenue

Figure 41 Valeant : Key Financials

Figure 42 Valeant : Segmental Revenue

Figure 43 Valeant : Geographical Revenue